China SXT Pharmaceuticals (NASDAQ:SXTC) Shares Down 0.4% – Here’s Why

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) was down 0.4% during mid-day trading on Thursday . The company traded as low as $2.38 and last traded at $2.57. 9,698 shares were traded during trading, a decline of 75% from the average session volume of 38,406 shares. The stock had previously closed at $2.58.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of China SXT Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, July 10th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

China SXT Pharmaceuticals Stock Down 4.7%

The business has a 50 day simple moving average of $2.04 and a 200-day simple moving average of $18.54. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.94 and a quick ratio of 7.76.

China SXT Pharmaceuticals (NASDAQ:SXTC) last announced its quarterly earnings data on Wednesday, July 1st. The company reported ($0.07) EPS for the quarter. The business had revenue of $0.26 million for the quarter.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. XTX Topco Ltd purchased a new stake in China SXT Pharmaceuticals in the 4th quarter worth about $36,000. Virtu Financial LLC lifted its holdings in China SXT Pharmaceuticals by 107.5% during the third quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock valued at $46,000 after purchasing an additional 15,013 shares during the last quarter. Finally, Citadel Advisors LLC purchased a new stake in China SXT Pharmaceuticals during the third quarter valued at about $78,000. Institutional investors own 5.02% of the company’s stock.

China SXT Pharmaceuticals Company Profile

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.